The use of the psychological flexibility model to support psychedelic assisted therapy
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Abstract Psychedelic assisted therapy comprises three stages: Preparation, Psychedelic Session, and Integration. Preparation is key for maximising the potential of a beneficial psychedelic experience and integration is important for prolonging improvements. The psychological flexibility model (PFM) appears to be a promising one to guide psychedelic preparation and integration. This paper proposes a model that utilises the PFM as informed by a previously published qualitative study of patient accounts of change processes in psilocybin therapy that identified themes of acceptance and connection as associated with positive outcomes. This new model, the ACE (Accept, Connect, Embody) model presents the six psychological flexibility processes, renamed and rearranged in an acceptance triad (defusion, present moment focus, willingness) and a connection triad (self as context, values, committed action). This paper describes the ACE model and how it is being used in an ongoing trial of psilocybin treatment for major depression. It also describes qualitative evidence supportive of the idea that psychological flexibility may be key to characterizing the processes of change involved in psilocybin assisted therapy for depression. These and other results suggest that psilocybin may be specifically increasing psychological flexibility and point to the possibility that psychotherapy approaches incorporating the PFM may serve as a means to deepen and extend the benefits of psilocybin treatment, thus bridging the experiential gap between a potent inner experience and an outer life better lived.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acceptance and commitment therapy: model, processes and outcomes
Hayes, S. C., Luoma, J. B., Bond, F. W., Masuda, A., & Lillis, J. (2006) · Behaviour Research and Therapy · doi:10.1016/j.brat.2005.06.006 · Cited by 6,587
Self-citationThe necessary and sufficient conditions of therapeutic personality change.
Rogers, C. R. (1957) · Journal of Consulting Psychology · doi:10.1037/h0045357 · Cited by 5,599
Bond, F. W., Hayes, S. C., Baer, R. A., Carpenter, K. M., Guenole, N., Orcutt, H. K., Waltz, T., & Zettle, R. D. (2011) · Behavior Therapy · doi:10.1016/j.beth.2011.03.007 · Cited by 3,950
Psychological flexibility as a fundamental aspect of health
Kashdan, T. B., & Rottenberg, J. (2010) · Clinical Psychology Review · doi:10.1016/j.cpr.2010.03.001 · Cited by 3,054
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
(2011) · Cited by 1,181
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
A-Tjak, J. G. L., Davis, M. L., Morina, N., Powers, M. B., Smits, J. A. J., & Emmelkamp, P. M. G. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000365764 · Cited by 1,031
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Psychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657
Self-citation
Cited by
Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119897615 · Cited by 360
Psychedelics, mystical experience, and therapeutic efficacy: a systematic review
Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.917199 · Cited by 306
Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression
Murphy, R., Kettner, H., Zeifman, R., Giribaldi, B., Kartner, L., Martell, J., Read, T., Murphy-Beiner, A., Baker-Jones, M., Nutt, D., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.788155 · Cited by 250
“A psychedelic-specific therapy model, informed, in part, by ACT, emerged during the trial, and is referred to as The ACE model (Watts and Luoma, 2020).”
BackgroundMethodInfluentialSelf-citationHayes, S. C., Ciarrochi, J., Hofmann, S. G., Chin, F., & Sahdra, B. (2022) · Behaviour Research and Therapy · doi:10.1016/j.brat.2022.104155 · Cited by 234
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
van Elk, M., & Yaden, D. B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00748-y · Cited by 224
Psychedelic integration: an analysis of the concept and its practice
Bathje, G. J., Majeski, E., & Kudowor, M. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.824077 · Cited by 174
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis
Ko, K., Kopra, E. I., Cleare, A. J., & Rucker, J. J. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.168 · Cited by 150
Psychedelic harm reduction and integration: A transtheoretical model for clinical practice
Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.645246 · Cited by 147
“Psychedelic integration, including as it pertains to fearful reactions, may be useful in increasing psychological flexibility (Watts and Luoma, 2020).”
BackgroundEthical and legal issues in psychedelic harm reduction and integration therapy
Pilecki, B., Luoma, J. B., Bathje, G. J., Rhea, J., & Narloch, V. F. (2021) · Harm Reduction Journal · doi:10.1186/s12954-021-00489-1 · Cited by 141
Self-citationTherapeutic effect of psilocybin in addiction: A systematic review
van der Meer, P. B., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., de Waal, M. M., Goudriaan, A. E., Kramers, K., Schellekens, A., Somers, M., Bossong, M. G., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1134454 · Cited by 127
Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00018 · Cited by 124
Psychedelics and psychotherapy: Cognitive-behavioral approaches as default
Yaden, D. B., Earp, D., Graziosi, M., Friedman-Wheeler, D., Luoma, J. B., & Johnson, M. W. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.873279 · Cited by 110
Self-citationZeifman, R. J., Wagner, A. C., Watts, R., Kettner, H., Mertens, L. J., & Carhart-Harris, R. L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00782 · Cited by 106
“gov, NCT 03429075) in which we are integrating components of ACT with psilocybin for major depression [see (94); also, see (97)].”
BackgroundMethodSelf-citationDoes Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Kočárová, R., Horáček, J., & Carhart-Harris, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.661233 · Cited by 96
Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94
“aged to engage in intention setting [192].”
BackgroundBrennan, W., & Belser, A. B. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.866018 · Cited by 90
“Mindfulness in EMBARK has significant conceptual overlap with the notion of “psychological flexibility” that the ACE Model (Watts and Luoma, 2020) derives from ACT.”
BackgroundInfluentialThe therapeutic potential of psilocybin: a systematic review
van Amsterdam, J., & van den Brink, W. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047929 · Cited by 74
Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”
Spriggs, M. J., Douglass, H. M., Park, R. J., Read, T., Danby, J. L., de Magalhães, F. J. C., Alderton, K. L., Williams, T. M., Blemings, A., Lafrance, A., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.735523 · Cited by 75
van Oorsouw, K., Toennes, S. W., & Ramaekers, J. G. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06046-9 · Cited by 74
Davis, A. K., Xin, Y., Sepeda, N. D., Garcia-Romeu, A., & Williams, M. T. (2021) · Chronic Stress · doi:10.1177/24705470211035607 · Cited by 67
Stauffer, C. S., Anderson, B. T., Ortigo, K. M., & Woolley, J. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00169 · Cited by 65
Luoma, J. B., Sabucedo, P., Eriksson, J., Gates, N., & Pilecki, B. C. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.10.003 · Cited by 56
Self-citationEvens, R., Schmidt, M. E., Majić, T., & Schmidt, T. T. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231172254 · Cited by 56
“74,84,85 Results of this review can therefore not be generalized to uncontrolled and recreational contexts of drug administration where unpleasant and challenging experiences might not be cushioned by a holding environment.”
BackgroundPsychedelic-assisted psychotherapy: Where is the psychotherapy research
Aday, J. S., Horton, D., Fernandes-Osterhold, G., O’Donovan, A., Bradley, E. R., Rosen, R. C., & Woolley, J. D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06620-x · Cited by 54
Agin-Liebes, G., Zeifman, R., Luoma, J. B., Garland, E. L., Campbell, W. K., & Weiss, B. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221080165 · Cited by 54
“Given their putative overlapping mechanisms, there has been recent interest in the integration of classic psychedelics with contextual-based therapies, focused on psychological flexibility processes, to treat disorders characterized by emotional avoidance and maladaptive emotion regulation (Sloshower et al., 2020; Wat…”
BackgroundSelf-citationPsychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action
Rieser, N. M., Herdener, M., & Preller, K. H. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2021_284 · Cited by 37
Fang, S., Ding, D., Zhang, R., & Huang, M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1084467 · Cited by 25
“Therefore, enhancing psychological flexibility is a primary mechanism by which evidencebased psychotherapies produce adaptive behavioral change and related outcomes (39, 109, 110).”
BackgroundZamaria, J. A., Fernandes-Osterhold, G., Shedler, J., & Yehuda, R. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1505894 · Cited by 29
Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder
Brett, J., Knock, E., Korthuis, P. T., Liknaitzky, P., Murnane, K. S., Nicholas, C. R., Patterson, J. C., & Stauffer, C. S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1123424 · Cited by 16
Johansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin-Purcell, L., & Murray, G. (2022) · Systematic Reviews · doi:10.1186/s13643-022-01930-7 · Cited by 11
“An acceptance and commitment therapeutic framework has been utilised in a trial with a depressed sample [17, 46].”
MethodKnock, E., Siefried, K. J., Bedi, G., Albert, S., Day, R. O., Ezard, N., Ross, M., Liknaitzky, P., & Brett, J. (2025) · Addiction · doi:10.1111/add.70187 · Cited by 9
Metadata
- Authors
- Watts, R., & Luoma, J. B.
- Venue
- Journal of Contextual Behavioral Science
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 15
- Pages
- 92-102
- ISSN
- 2212-1447 (ISSN-L)
- OpenAlex
- W2996321268
- Cited by
- 269
- References
- 24
- FWCI
- 23.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.